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Abstract
Background
Major protease mutations are rarely observed following failure with protease inhibitors (PI),
and other viral determinants of failure to PI are poorly understood. We therefore character-
ized Gag-Protease phenotypic susceptibility in subtype A and D viruses circulating in East
Africa following viral rebound on PIs.
Methods
Samples from baseline and treatment failure in patients enrolled in the second line LPV/r
trial SARA underwent phenotypic susceptibility testing. Data were expressed as fold-
change in susceptibility relative to a LPV-susceptible reference strain.
Results
We cloned 48 Gag-Protease containing sequences from seven individuals and performed
drug resistance phenotyping from pre-PI and treatment failure timepoints in seven patients.
For the six patients where major protease inhibitor resistance mutations did not emerge,
mean fold-change EC50 to LPV was 4.07 fold (95% CI, 2.08–6.07) at the pre-PI timepoint.
Following viral failure the mean fold-change in EC50 to LPV was 4.25 fold (95% CI, 1.39–
7.11, p = 0.91). All viruses remained susceptible to DRV. In our assay system, the major PI
resistance mutation I84V, which emerged in one individual, conferred a 10.5-fold reduction
in LPV susceptibility. One of the six patients exhibited a significant reduction in susceptibility
between pre-PI and failure timepoints (from 4.7 fold to 9.6 fold) in the absence of known
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major mutations in protease, but associated with changes in Gag: V7I, G49D, R69Q,
A120D, Q127K, N375S and I462S. Phylogenetic analysis provided evidence of the emer-
gence of genetically distinct viruses at the time of treatment failure, indicating ongoing viral
evolution in Gag-protease under PI pressure.
Conclusions
Here we observe in one patient the development of significantly reduced susceptibility con-
ferred by changes in Gag which may have contributed to treatment failure on a protease
inhibitor containing regimen. Further phenotype-genotype studies are required to elucidate
genetic determinants of protease inhibitor failure in those who fail without traditional resis-
tance mutations whilst PI use is being scaled up globally.
Introduction
It is estimated that almost 15 million HIV-infected people in resource limited settings are cur-
rently being treated with antiretroviral therapy[1]. Most will have started ART with a PI-spar-
ing regimen, as recommended by WHO guidelines[2], leaving the PI class available for use in
combination second-line therapy. The use of boosted protease inhibitor monotherapy (bPI-
mono) as maintenance therapy has been investigated in a number of trials in resource-rich set-
tings, which have suggested that this strategy can be considered under certain circumstances
[3–7]. The Boosted Protease Inhibitor Monotherapy as Maintenance Second-line Anti-retrovi-
ral therapy in Africa (SARA) trial, was a nested pilot study within the DART trial[8] designed
to test whether ritonavir boosted lopinavir (LPV/r) monotherapy (bPImono) after an initial
24 weeks on second-line combination therapy provided similar outcomes to continuation
on combination second-line therapy (CT) [9]. 192 patients who had experienced clinical/
immunological failure on first-line therapy in the DART trial [8] and had received 24 weeks
of second-line LPV/r containing therapy were randomized and the trial demonstrated non-
inferiority of LPV/r monotherapy in CD4+ T cell response and rate of serious adverse events
(SAEs). However, viremia (50 copies/mL) was more common 24 weeks after randomization
in the bPImono arm (23% CT vs 40% bPImono, p = 0.01). Major resistance mutations in prote-
ase [10] were detected in 5/20 (25%) bPImono participants with a VL>1000 copies/ml at 24
weeks/last time-point with successful genotyping (compared to 0/8 CT)[9]. More recently, the
larger EARNEST trial (also conducted in sub Saharan Africa) showed inferiority of a PI mono-
therapy approach to triple therapy over 2 years of follow up [11], though detailed genotypic
resistance data have not been published.
Clinical studies of PI-based combination regimens have previously highlighted our poor
understanding of determinants of virological failure to this drug class when assessed by prote-
ase genotyping alone [12–15]. Protease genotyping and phenotyping remains the standard in
commercial systems and clinical trial settings. By contrast, in research settings, mutations in
gag have been shown to affect PI susceptibility directly and have been associated with treatment
failure where accompanied by major protease mutations (as reviewed by Fun et al. [16]). Inclu-
sion of co-evolved Gag alongside protease in phenotypic assays enables more accurate mea-
surement of PI susceptibility than protease alone [17]. Recently we noted lower inherent PI
susceptibility of subtype AG and G viruses (which circulate mainly in West Africa) as com-
pared to subtype B viruses (known to predominate in western Europe and North America),
using a full-length gag-protease assay [18]. Furthermore, studies have described mutations in
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Gag in subtype C viruses associated with PI and exposure and treatment failure but their direct
effect on susceptibility was not reported [19, 20] Given that gag is polymorphic between HIV-1
subtypes, assessments of PI susceptibility using such assays are warranted across regions and
subtypes in the context of PI exposure.
We set out to investigate PI susceptibility of full-length Gag-Protease containing viruses,
derived from SARA trial participants harbouring HIV-1 subtypes A and D from Uganda. The
ability to perform genotypic and phenotypic resistance testing before PI exposure and after PI-
containing therapy failure offered a unique opportunity to explore the determinants of treat-
ment failure in viruses circulating in East Africa, where an estimated 4.6 million people are
HIV infected (http://www.unaids.org/en/regionscountries/countries).
Methods
Patients
Seven patients who experienced treatment failure in the SARA trial were studied and the pre-
PI and treatment failure timepoints samples assessed genotypically and phenotypically for each
patient. For this study, patients were considered to have failed therapy if they had a viral load
above 1,000 copies/mL at week 24 of the SARA trial. In SARA, viral load monitoring and resis-
tance testing were performed retrospectively and did not inform treatment decisions. Pre-PI
therapy was defined as the time at which the patient switched to second-line LPV/r containing
combination therapy (24 weeks before randomization in SARA)[9]. Four patients were selected
from the 20 SARA participants randomized to bPImono experiencing virological failure
(defined as VL>1000 copies/ml at week 24 and/or last visit) with successful protease resistance
genoptyping[9], based on the availability of sample or population sequence covering full-length
Gag-Protease from both pre-PI therapy and failure time-points–patients 2, 3, 4 and 6 (Suther-
land et al, in press AIDS Research and Human Retroviruses). Two of the eight patients
experiencing failure in the CT arm, patients 1 and 7 were also included. Patients with major
resistance mutations pre-PI therapy or at failure were excluded from our study cohort. How-
ever, patient 5 who failed with major resistance mutation I54V that was not present before
therapy was examined separately to assess the fold-change in PI susceptibility in our system
conferred by a known major PI resistance mutation. This facilitated comparison of fold-
changes in susceptibility with other studies, and put into context the magnitude of susceptibil-
ity changes observed within the present study. All clinical data were collected as part of the
SARA clinical trial. Data quality control was carried out in line with principles of good clinical
practice.
Ethics statement
Written informed consent for participation was obtained from participants. SARA received
ethics approval in Uganda (Uganda Virus Research Institute (UVRI) Science and Ethics Com-
mittee) and the UK (Imperial College). SARA is registered under ISRCTN53817258.
Genotypic testing methods
Standard genotypic resistance testing by RT-PCR covering protease was performed as previ-
ously described [21]. In addition, Gag-Protease was amplified for sequencing using one step
cDNA synthesis and first round PCR with primers ATT GTG TGA CTC TGG TAA CTA
GAG ATC CCT (HXB2 nucleotides 570–599) and antisense TCC TAA TTG AAC YTC CCR
AAR TCY TGA GT (HXB2 2799–2828), and second round PCR with primers TCT CTA GCA
GTG GCG CCC GAA CAG (HXB2 626–649) and GGC CAT TGT TTA ACY TTT GGD CCA
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TCC. (HXB2 2597–2623) Viral subtype of Gag-Protease was determined using REGA HIV-1
Subtyping tool[22]. Sequences were manually checked and edited using DNADynamo
software.
Cloning of patient derived Gag-Protease
For patients with available extracted RNA after routine viral load and genotypic resistance test-
ing, full-length gag-protease was amplified by cDNA synthesis and nested PCR as previously
described [23]. Clonal analysis was performed for at least six viral variants at each timepoint
and the variant most similar to the population sequence selected for phenotyping. Sequences
were analysed in DNADynamo and manually examined for mixed bases and errors such as
stop codons or frameshift mutations. When RNA extract was not available, but genotyping of
gag and pol had been successfully performed, the population gag-protease sequence was synthe-
sized (GenScript, USA). Synthesis was performed for patient 2, 4 and 7 failure timepoints, and
patient 6 pre-PI and failure timepoints. Full-length gag-protease was cloned into the Gag-Pol
expression vector p8.9NSX+ using unique NotI and XhoI restriction sites as previously
described [23, 24].
PI susceptibility and single-round infectivity
PI susceptibility and single-round infectivity were measured using cell-based, single replica-
tion-cycle phenotypic assays, as previously described [24]. Briefly, 293T cells were co-trans-
fected with the Gag-Pol expression vector, VSV-g envelope vector and luciferase reporter
vector and incubated with serial dilutions of PI 18 hours post-transfection to measure suscepti-
bility. Infectivity was measured in fresh 293T cells using SteadyGlo luciferase substrate (Pro-
mega) and EC50 calculated using logistic regression, expressed as a fold-change compared with
the p8.9NSX+ reference strain. Susceptibility was measured to the PIs lopinavir (LPV) and dar-
unavir (DRV), obtained from the NIH AIDS Reagent Program. Single-round infectivity was
measured by infection of 293T cells in the absence of drug, with virus produced by transfection
of 293Ts as described above and harvested 48 hours post-transfection. PI susceptibility and sin-
gle round infectivity data presented here are means of at least two independent experiments.
Two-tailed, paired t-tests were performed, with P> 0.05 considered statistically significant,
using Graph Pad PRISM 5 software (La Jolla, CA, USA).
Phylogenetic analysis
Phylogenetic analyses were carried out for patients where multiple clonal sequences were avail-
able at both timepoints. Nucleotide sequences from pre-PI therapy and treatment failure time-
points of Gag-Protease were aligned in MEGA6 software [25] using the ClustalW algorithm
and phylogeny construction performed in PHYLIP (http://evolution.genetics.washington.edu/
phylip.html) using the maximum likelihood method under the generalized time reversible
(GTR) model. Trees were constructed with 500 bootstrap replicates and viewed using FigTree
v1.3.1 software (http://tree.bio.edu.ac.uk/software/figtree/) and MEGA6 software.
Results
To explore the determinants of treatment failure, we investigated whether reduced susceptibil-
ity before PI therapy, or the development of reduced PI susceptibility during therapy in the
absence of major resistance mutations, may have contributed to treatment failure in this popu-
lation of treatment-experienced patients. Viral load trajectories and treatment histories of the
six participants are shown in Fig 1.
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Three patients were infected with subtype A (patient 5, 6 & 7) and four with subtype D
(patient 1–4) by protease sequencing performed as part of standard resistance testing during
the trial[9] Following our full-length gag-pro sequencing we established that two patients ini-
tially classified as being infected with subtype D viruses were in fact infected with a recombi-
nant form comprising a stretch in matrix from subtype A with the rest of gag-pro being
subtype D (patients 1 and 4). All four individuals in the bPImono arm for whom a viral load
measurement was available at the time of simplification to monotherapy (after 24 weeks of PI-
containing combination therapy, patients 3, 4, 5 and 6), had a viral load below limit of quantifi-
cation (<50 copies/ml), including patient 5 who failed with major resistance mutations, dem-
onstrating adequate adherence and drug potency at this early time point. Interestingly, patient
2 did demonstrate a significant reduction in viral load after switch to PI containing therapy,
although no measurement at week 0 was available and experienced failure with a comparatively
low viral load– 1164 copies/mL. Most patients were switched from a first-line regimen of ZDV/
3TC/TDF to second-line regimens containing efavirenz (EFV) and either didanosine (ddI) or
lamivudine (3TC) with ritonavir boosted lopinavir (LPV/r). However, patient 4 was switched
to a two drug regimen comprising only EFV and LPV/r (Fig 1). Of note, patients 1 and 7 did
not achieve viral load suppression after switch to LPV/r containing second-line therapy despite
randomization to continuation on combination therapy in SARA, which could suggest poor
adherence to treatment (Fig 1). Both developed the K103N major NNRTI resistance mutation
conferring high level resistance to EFV at failure, and in addition patient 1 had mutations pre-
dictive of intermediate level resistance to ddI pre-PI and at failure.
Comparison of Gag-protease sequences derived from pre-PI and failure timepoints was per-
formed for each patient and amino acid changes present at failure in comparison with the pre-
PI timepoint noted (Table 1). In patients 1 and 3, only two amino acid changes were present at
failure, but in the remaining patients numerous mutations were present (Table 1). However,
no pattern of mutations was present across patients. Patient 5 developed major resistance
mutations I54V and I84V in protease at failure, along with 31 other mutations including
A431V and P453L in Gag that have been previously associated with PI exposure and resistance
[16].
Susceptibility to LPV, the PI used as treatment in the study, and the second generation PI
DRV (sometimes available as third line/salvage therapy in resource limited settings) was mea-
sured using an established phenotypic drug resistance assay. We tested viruses present in
patients pre-PI therapy (at the time of switch to second-line LPV/r containing combination
therapy—24 weeks before SARA enrollment) and at failure (at least 24 weeks after SARA
enrollment and randomization)—the timing of the samples in context with viral load and trial
week is shown Fig 1. Fig 2 shows the fold-change in PI susceptibility for pre-PI and treatment
failure viruses from each patient experiencing failure without major resistance mutations
(patients 1–4, 6 & 7) to the PIs LPV and DRV. For viruses derived from the pre-PI time-point,
the mean fold-change in EC50 to the PI LPV was 4.07 fold (95% CI, 2.08–6.07) relative to the
clade B assay reference strain and 2.00 fold (95% CI, 1.19–2.80) to DRV (Fig 2). At failure the
mean fold-change in EC50 to LPV and DRV was 4.50 fold (95% CI, 0.82–8.19) and 1.71 fold
Fig 1. Viral load and patient treatment information. Treatment history of each patient is shown, from switch to second-line therapy during the DART trial
(week -24, BL) and their enrollment in SARA (week 0), shown for most patients by simplification to LPV/r monotherapy. All patients were randomised to the
LPV/r monotherapy arm of the SARA trial except for patients 1 and 7, who were randomised to continue on LPV/r containing triple therapy (CT). Available
viral load measurements are shown; these were performed retrospectively and did not inform treatment decisions. The limit of detection for the assay (<50
copies/mL) is denoted with a red dashed line. The time from which the pre-PI (baseline, BL) and failure (Fail) samples included in this study were derived is
highlighted by grey bars. For patient 7, the pre-PI sample was derived from week 0 of the DART trial before the week -24 of SARA timepoint, hence is not
shown on this graph.
doi:10.1371/journal.pone.0137834.g001
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(95% CI, 0.97–2.46), respectively. There was no statistically significant change in susceptibility
between pre-PI and failure time points for either LPV (Fig 2A, p = 0.91) or DRV (Fig 2B, p =
0.78). In an analysis of replication capacity, there was no significant change in single-round
infectivity between pre-PI therapy and failure viruses (p = 0.07) (Fig 2C).
Patient 5 was included to measure the effect of major resistance mutations in a subtype spe-
cific background in our phenotypic assay. Population genotypic resistance testing had identi-
fied the I54V resistance mutation alongside the A431V compensatory Gag mutation at the
time of failure [26]. Our clonal analysis also identified the I84V major resistance mutation
present in two of seven failure variants in the absence of A431V or I54V. Both the I54V/A431V
and I84V variants tested separately displayed 10–17 fold reductions in susceptibility in com-
parison with the clade B reference strain, illustrating the level of reduced susceptibility that a
single major protease resistance mutations confer in our assay system (Fig 3A). Comparison of
EC50 values between the pre-PI and failure timepoint showed a 3.28 and 3.62 fold reduction in
susceptibility conferred by the development of the major mutations I84V and I54V respectively
(S1 Table).
Phenotyping data revealed that patient 6 was of particular interest. Patient 6 was infected
with a subtype A virus and experienced virological failure on LPV/r monotherapy in the
absence of major PI resistance mutations. We detected a significant decrease in susceptibility
to LPV from 4.7 fold pre-PI to 9.6 fold at the time of treatment failure in the absence of major
resistance mutations or any other mutations in protease between the pre-PI and failure time-
points, correlating with a 2-fold increase in LPV EC50 (Fig 3B and S1 Table). This reduction in
susceptibility did however correlate with the appearance of a number of amino acid changes in
Gag (V7I, G49D, R69Q, A120D, Q127K, N375S and I462S). One of these, N375S, is located in
the p2/NC cleavage site and has been previously reported to be associated with PI exposure in
vivo[27, 28].
For patients where sample availability enabled clonal analysis at both pre-PI therapy and
failure time-points, phylogenetic reconstruction of the available sequences was performed to
examine the genetic relationship of the viruses before and after PI exposure. In each case, the
phylogenetic trees provide evidence for the emergence of a genetically distinct viral population
at the time of treatment failure in comparison with pre-PI therapy, indicating ongoing viral
Table 1. Amino acid changes inGag-protease at time of treatment failure relative to pre-PI Gag-Prote-
ase sequence in study participants.
Mutations at Treatment Failure, not present at the Pre-PI Timepoint
Patient Gag Protease
1 R26K, G387S -
2 L46I, R91G, A95K, T109A, S111F, N124S, S239T, R268K V13I
3 V34I I77V
4 L34I, A37P, D42E, Q59M, K69R, L90E, T122A, N389I, Q468E, V469I,
P473S, T487A
I13V, V72I
5 K26R, R30Q, E62A, T72S, Y79F, A81T, V82T, H89Q, R91Q, I94V,
N124S, K127T, T138A, M142W, T144H, V147L, V215I, S252G, T332S,
K335R, T339A, R406K, A431V*, P453L, L462I, G466R, S472F, N479S,
E482D
I54V*, R57K, P63L,
I84V*
6 V7I, G49D, R69Q, A120D, Q127K, N375S, I462S -
7 S38G, A67T, N127K, K361R, P473A -
*I54V and I84V were not present in the same viral clone, but were present on separate clones. A431V
developed only in the clones with I54V. ‘-‘) denotes when no changes in protease were present at failure.
doi:10.1371/journal.pone.0137834.t001
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replication and evolution during LPV/r monotherapy (Fig 4). For patients 1 and 3, a clear sepa-
ration of pre-PI therapy and failure variants was present, but this separation was not statisti-
cally supported–most likely due to the close relatedness of intrapatient viral variants (Fig 4A
and 4C). Separation was particularly evident, and supported statistically, in patient 5 (Fig 4B)
where the failure viruses formed a distinct cluster with a comparatively long branch length. Of
note, Fig 4B was constructed using an alignment stripped of resistance positions 431 in Gag
and 54 and 84 in protease, indicating that the evolution driven by PI exposure is not restricted
to the classically described resistance positions. Phylogenetic reconstruction performed with
these resistance positions resulted in an identical tree (data not shown).
Fig 2. PI susceptibility and single round infectivity of patient Gag-Protease derived pre-PI therapy and at the time of treatment failure. Full-length
Gag-Protease from pre-PI therapy and failure time-points was amplified or synthesised, and cloned into our Gag-Pol expression vector p8.9NSX+. PI
susceptibility of VSV-g pseudotyped viruses from patients experiencing virological failure in the absence of major resistance mutations was measured in a
cell-based, single-round, phenotypic assay to the PIs A) Lopinavir (LPV) and B) Darunavir (DRV). The patient numbers are shown for each data point and
data are means of two independent repeats. Our data demonstrate no significant difference in susceptibility between pre-PI therapy and failure viruses to the
PIs LPV (t test, p = 0.91) and DRV (t test, p = 0.78), in patients failing in the absence of major resistance mutations. (C) Single-round infectivity of viruses was
measured in the absence of drug in HEK 293T cells and compared in patients failing without major resistance mutations. No significant decrease in single-
round infectivity was present (t test, p = 0.07).
doi:10.1371/journal.pone.0137834.g002
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Discussion
The global scale-up of antiretroviral therapy has resulted in increasing numbers of patients
experiencing virologic failure and qualifying under WHO guidelines for switch to PI-contain-
ing second-line therapy (mostly LPV/r due to availability of a heat stable co-formulation of
lopinavir and ritonavir). Of those experiencing PI failure, only a minority have resistance
detectable by standard approaches to drug resistance testing. As may be expected studies have
linked suboptimal PI concentrations with poorer therapy outcomes [29, 30], but there remains
a need for greater understanding of the determinants of PI therapy failure as these drugs
become more widely used in populations infected with divergent HIV-1 strains. We have
therefore applied a Gag-Protease phenotypic susceptibility assay to six patients failing PI-based
therapy in the SARA trial who had no detectable protease resistance mutations, and one patient
who did develop major protease resistance mutations.
Overall, amongst the six patients failing without major protease mutations we observed no
significant difference in PI susceptibility between pre-PI therapy and failure viruses, indicating
that treatment failure on LPV/r is unlikely to be solely attributable to the development of
reduced susceptibility under PI pressure (Fig 2). This is in agreement with findings for patients
enrolled in the French MONARK PI monotherapy clinical trial [31]. Furthermore, viruses
present pre-PI therapy were relatively susceptible to LPV displaying fold-changes in suscepti-
bility to LPV below 5 (mean fold-change 4.07). In this cohort, there was no evidence that
reduced susceptibility at baseline may have contributed to treatment failure which contrasts
with our findings in subtype CRF02_AG viruses from patients failing PI in MONARK that dis-
played mean baseline fold change of 10.4 at baseline (17).
A single patient (6) displayed a significant reduction in susceptibility at failure in compari-
son with pre-PI therapy viruses, accompanied by amino acid changes in Gag only. These
changes in Gag conveyed a similar reduction in LPV susceptibility to the major PI resistance
mutations I54V or I84V present singly at failure for patient 5 (Fig 3). This observation is
Fig 3. PI susceptibilities of pre-PI and failure virus from two patients demonstrate changes in phenotypic susceptibility over time. Full-length Gag-
Protease sequences from pre-PI therapy and failure time-points was amplified or synthesised, and single round phenotypic susceptibility testing performed.
PIs tested were Lopinavir (LPV) and Darunavir (DRV). (A) Susceptibility data from patient 5 demonstrates the reduction in susceptibility conferred by major
mutations I84V (black) and I54V (grey) in our system in comparison with the patient virus at pre-PI therapy (white). Error bars represent standard deviation of
two independent experimental repeats. (B) Virus derived pre-PI therapy (white bar) and at time of failure (black bar) from patient 6 demonstrated a difference
in susceptibility to LPV in the absence of the development of major resistance mutations.
doi:10.1371/journal.pone.0137834.g003
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reminiscent of the MONARK resistance analysis, where one in four developed reduced PI sus-
ceptibility during therapy, correlating with the emergence of three changes in Gag as well as
the secondary mutation M36I in protease [31]. These observations are in-keeping with other
studies demonstrating that amino acid positions in Gag can directly affect susceptibility to pro-
tease inhibitors, independent of compensating for reduced fitness following emergence of
major resistance mutations [32–35]. Taken together, these studies indicate that the develop-
ment of reduced susceptibility during PI therapy in the absence of protease resistance muta-
tions may contribute to treatment failure in a subset of patients and further exploration of the
genetic determinants in Gag is required. It is likely that this reduced susceptibility may render
the patient more likely to experience treatment failure when therapy adherence is suboptimal.
In the remaining patients the causes of treatment failure on PI regimens remain unknown.
It is likely that poor adherence may have contributed to treatment failure in some patients,
but in the absence of plasma drug concentrations the exact role is unknown. For patients 1 and
7 randomised to the continuation arm it is clear that the development of K103N, a major
NNRTI resistance mutation conferring high-level resistance to EFV, may have contributed to
treatment failure. However, given that susceptibility to PIs was maintained it could be argued
that the patients were effectively receiving PI monotherapy, as the RTIs in their regimen were
compromised by resistance, and that viral suppression should still have been maintained.
Fig 4. Maximum Likelihood phylogeny of virus from pre-PI therapy and treatment failure timepoints.
Phylogenetic reconstruction was performed using the GTRmodel of nucleotide substitution. Phylogeny for
the three patients for whommultiple sequences from both baseline and failure timepoints is shown: (a) patient
1, (b) patient 5 and (c) patient 3. Pre-PI virus sequences are denoted with circles and failure virus sequences
with triangles. For patient 5 the drug resistance positions Gag 431 and Protease 54 and 84 were stripped
from the alignment before phylogenetic re-construction. Nodes separating pre-PI and failure variants that
supported by >75% bootstrapping are depicted with an asterisk (*).
doi:10.1371/journal.pone.0137834.g004
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Further research to explore the determinants of treatment failure in patients receiving PI-con-
taining combination therapies is urgently required, given that these are the regimens most fre-
quently utilised in resource limited settings.
Of note, we frequently found evidence of ongoing viral evolution during LPV/r monother-
apy using phylogenetic analysis, despite observing no change in phenotypic susceptibility. This
evolution could be impacting susceptibility in ways that are not assessed in our assay, for exam-
ple involving coevolution with envelope mutations as suggested by Rabi et al. [36], or other
routes which could be addressed in the future using patient derived full-length viruses. Other
limitations of this study include the sample size, largely driven by sample availability and
amplification efficiency, and sometimes necessitating the use of commercial gene synthesis.
Patient Gag-Protease was assessed in a subtype B backbone and it is possible that this may have
affected replication fitness, although this backbone has also been used with subtype C, AG and
G viruses[17, 31]. We hypothesise that the increase in susceptibility at failure observed here for
patient 4, which is puzzling and not in-keeping with the rest of our patient observations, could
be a result of coevolution of Gag-Protease with regions outside those included in our assay. It is
also possible that the synthesis of a population sequence at the failure timepoint, rather than
clonal analysis, has resulted in the inclusion of mutations that would not actually be found on
the same genomes within the patient and are therefore not naturally coevolved.
Although small sample size is a limitation of this study, paired samples taken before treat-
ment and at failure are difficult to obtain and very little data on PI susceptibility of Gag-Prote-
ase in non-B subtypes within a clinical setting exists. To date a single study has examined PI
susceptibility of Gag-Protease from subtype A viruses, demonstrating the value of including
Gag in phenotypic analysis, but this study did not include paired samples taken pre- and post-
therapy[17]. To our knowledge there are no data for subtype D clinical isolates. Here, the iden-
tification of recombinants precluded assessment of impact of subtype on drug susceptibility.
In conclusion, we have performed the first detailed phenotypic analysis of PI-therapy failure
using co-evolved Gag-Protease in viruses that predominate in East Africa. We provide further
evidence that the development of reduced PI susceptibility during LPV/r based treatment in
the absence of major resistance mutations, albeit in only a single patient and we hypothesise
that this may contribute to treatment failure in a small subset of patients. In these and other
patients failing PI, suboptimal adherence is likely to be a key contributory factor. Importantly,
our study also suggests that in patients experiencing relatively early failure on LPV, viruses
remain fully susceptible to DRV- a drug that may be used as a salvage therapy option for these
patients in the future.
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